RNAC – cartesian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cartesian Therapeutics (NASDAQ:RNAC) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Cartesian Therapeutics (NASDAQ:RNAC) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at BTIG Research from $42.00 to $44.00. They now have a "buy" rating on the stock.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership [Yahoo! Finance]
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Form 4 Cartesian Therapeutics, For: Nov 28 Filed by: English Emily
Form 4 Cartesian Therapeutics, For: Nov 18 Filed by: Singer Michael
Form 144 Cartesian Therapeutics, Filed by: Jewell Christopher M
Form 10-Q Cartesian Therapeutics, For: Sep 30
Form 8-K Cartesian Therapeutics, For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.